Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05515263
Other study ID # HR/DP-21/22-33040
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 9, 2022
Est. completion date June 2024

Study information

Verified date July 2023
Source King's College London
Contact Alice van der Schoot, MSc
Phone 020 7848 4552
Email nutrimmune@kcl.ac.uk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the impact of replacing usual snacks with alternative snack foods on the immune response to influenza vaccination in a population of healthy, middle-aged adults.


Description:

Nutrition plays an important role in the immune system by providing energy and metabolites to support the function of immune cells, allowing them to initiate effective immune responses. Diet is therefore a modifiable factor in impacting immune function and is currently a topic of substantial interest in health research. Snack consumption has been shown to account for approximately 20-30% of daily energy intake in adults. Therefore, snack choices have the potential to influence dietary intake and quality, and therefore immune function, both positively and negatively. This study assesses the effect of replacing usual snacks with alternative snack foods on the immune response in a model of viral infection - the seasonal influenza vaccine containing four prevalent influenza virus strains for the 2022/23 or 2023/24 influenza season, as determined by the World Health Organization. This study is a parallel group, randomised controlled trial that will examine the replacement of usual snack foods with alternative snack foods on the immune response to seasonal influenza vaccination in humans, which will be assessed by measuring rates of seroconversion, and other immunological markers following vaccination. The intervention will be for 8 weeks, and influenza vaccination will be administered at 4-week midpoint. Participants will be followed up 3 months post-vaccination to assess incidence of upper respiratory symptoms.


Recruitment information / eligibility

Status Recruiting
Enrollment 88
Est. completion date June 2024
Est. primary completion date June 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 64 Years
Eligibility Inclusion Criteria: 1. Men or women, aged between 40-64 years 2. Body mass index (BMI) of 18.50 - 29.99 kg/m2 3. Individuals who regularly consume snacks (=2 per day, excluding fruit, vegetable, nut and seed snacks) 4. Fibre intake <30 g/d 5. Willing to avoid receiving any vaccination (except for COVID-19 vaccination) from one month prior to the baseline visit until completion of the 8-week intervention period 6. Willing to avoid receiving any COVID-19 vaccination/booster between week 2 and week 8 of the intervention period 7. Willing to discontinue use of prebiotics and probiotics during the trial 8. Willing to follow the protocol and provide consent Exclusion Criteria: 1. Allergy or intolerance to any intervention products 2. Dislike of any intervention products 3. Immunodeficiency/immunosuppression due to disease or medication, such as: - Chronic inflammatory disease or autoimmune disease (e.g., rheumatoid arthritis, inflammatory bowel disease, psoriasis) or primary or secondary immunodeficiency disease (e.g., HIV infection) - Ongoing therapy with immunomodulators or immunosuppressants (e.g., chemotherapy, oral corticosteroids, daily use of inhaled or nasal corticosteroids) - Other immunodeficient state (e.g., asplenia). 4. Medical history of any of the following: diabetes, major active psychiatric conditions (e.g. schizophrenia), current eating disorder, alcohol abuse, active treatment for cancer in the last year, severe neurological, endocrine, renal, cardiac or pulmonary disease (or any other chronic medical condition), severe oesophagitis, gastritis or duodenitis, active diverticulitis or intestinal/colonic strictures, Coeliac disease, Crohn's disease or Ulcerative colitis, stem cell or organ transplant, gut resection surgery, bleeding disorder, anaphylaxis or any other major or chronic condition known to impact study outcome measures. 5. Ongoing use of antiviral agents, or any other drugs known to impact study outcome measures 6. Use of immunoglobulins and/or any blood products within the three months prior to vaccination 7. Ongoing use of anticoagulants (e.g., warfarin) 8. Antibiotic treatment in the month prior to the start of the study 9. Consumption of probiotics or prebiotic products within the four weeks prior to the start of the study 10. History of severe adverse reaction and/or allergic reaction associated with the influenza vaccine or any other vaccine 11. Known allergy or hypersensitivity to any component of the vaccine including: sodium chloride, potassium chloride, magnesium chloride hexahydrate, disodium phosphate dihydrate, potassium dihydrogen phosphate; and possible trace residues: beta-propiolactone, cetyltrimethylammonium bromide, and polysorbate 80 12. Suffered from influenza illness in the six months prior to the start of the study 13. For participants recruited on or before 30/06/2023, exclusion criteria is: already vaccinated with any influenza vaccine licensed for the 2022/2023 season; For participants recruited after 30/06/2023, exclusion criteria is: already vaccinated with any influenza vaccine licensed for the 2023/2024 season 14. Received any influenza vaccination within six months prior to the start of the study 15. Received any other vaccinations within one month prior to the start of the study (except for COVID-19 vaccination) 16. Women who are pregnant, lactating or planning pregnancy 17. Ongoing alcohol, drug or medication abuse 18. Unexplained or unintentional weight loss in the past six months

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Intervention snack
To be eaten in replacement of usual snacks twice a day for 8 weeks.
Control snack
To be eaten in replacement of usual snacks twice a day for 8 weeks.

Locations

Country Name City State
United Kingdom King's College London London

Sponsors (1)

Lead Sponsor Collaborator
King's College London

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rates of seroconversion for =1 influenza virus strain The proportion of participants achieving seroconversion (=4-fold increase in specific antibody titre) in at least one influenza virus strain. Titres will be assessed using the Hemagglutination Inhibition Assay (HAI) and fold change will be calculated. Week 8
Secondary Rates of seroconversion for A/Wisconsin/588/2019 (H1N1)pdm09-like virus strain (strain 1a) The proportion of participants achieving seroconversion for A/Wisconsin/588/2019 (H1N1)pdm09-like virus strain. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for A/Wisconsin/67/2022 (H1N1)pdm09-like virus strain (strain 1b) The proportion of participants achieving seroconversion for A A/Wisconsin/67/2022 (H1N1)pdm09-like virus strain. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for A/Darwin/6/2021 (H3N2)-like virus strain (strain 2) The proportion of participants achieving seroconversion for A/Darwin/6/2021 (H3N2)-like virus strain. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for influenza virus B/Austria/1359417/2021 (B/Victoria lineage)-like virus strain (strain 3) The proportion of participants achieving seroconversion for B/Austria/1359417/2021 (B/Victoria lineage)-like virus strain. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for B/Phuket/3073/2013 (B/Yamagata lineage)-like virus strain (strain 4) The proportion of participants achieving seroconversion for B/Phuket/3073/2013 (B/Yamagata lineage)-like virus strain. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Proportion of participants who do not achieve seroconversion for any influenza virus strain Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for only 1 influenza virus strain The proportion of participants achieving seroconversion for 1 influenza virus strain. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for 2 influenza virus strains The proportion of participants achieving seroconversion for 2 influenza virus strains. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for 3 influenza virus strains The proportion of participants achieving seroconversion for 3 influenza virus strains. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Rates of seroconversion for 4 influenza virus strains The proportion of participants achieving seroconversion for all 4 influenza virus strains. Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Geometric mean antigen-specific titres for or A/Wisconsin/588/2019 (H1N1)pdm09-like virus strain (strain 1a) Titres will be assessed by HAI. Week 0, 4 and 8
Secondary Geometric mean antigen-specific titres for A/Wisconsin/67/2022 (H1N1)pdm09-like virus strain (strain 1b) Titres will be assessed by HAI. Week 0, 4 and 8
Secondary Geometric mean antigen-specific titres for A/Darwin/6/2021 (H3N2)-like virus strain (strain 2) Titres will be assessed by HAI. Week 0, 4 and 8
Secondary Geometric mean antigen-specific titres for B/Austria/1359417/2021 (B/Victoria lineage)-like virus strain (strain 3) Titres will be assessed by HAI. Week 0, 4 and 8
Secondary Geometric mean antigen-specific titres for B/Phuket/3073/2013 (B/Yamagata lineage)-like virus strain (strain 4) Titres will be assessed by HAI assay. Week 0, 4 and 8
Secondary Fold change in antigen-specific titres for A/Wisconsin/588/2019 (H1N1)pdm09-like virus strain (strain 1a) Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Fold change in antigen-specific titres for A/Wisconsin/67/2022 (H1N1)pdm09-like virus strain (strain 1b) Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Fold change in antigen-specific titres for A/Darwin/6/2021 (H3N2)-like virus strain (strain 2) Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Fold change in antigen-specific titres for B/Austria/1359417/2021 (B/Victoria lineage)-like virus strain (strain 3) Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Fold change in antigen-specific titres for B/Phuket/3073/2013 (B/Yamagata lineage)-like virus strain (strain 4) Titres will be assessed by HAI and fold change will be calculated. Week 8
Secondary Seroprotection for =1 influenza virus strain The proportion of participants achieving seroprotection (HAI titre of =1:40) in at least one of the four influenza virus strains. Week 8
Secondary Seroprotection for A/Wisconsin/588/2019 (H1N1)pdm09-like virus strain (strain 1a) The proportion of participants achieving seroprotection (HAI titre of =1:40) for A/Wisconsin/588/2019 (H1N1)pdm09-like virus strain. Week 8
Secondary Seroprotection for A/Wisconsin/67/2022 (H1N1)pdm09-like virus strain (strain 1b) The proportion of participants achieving seroprotection (HAI titre of =1:40) for A/Wisconsin/67/2022 (H1N1)pdm09-like virus strain. Week 8
Secondary Seroprotection for A/Darwin/6/2021 (H3N2)-like virus strain (strain 2) The proportion of participants achieving seroprotection (HAI titre of =1:40) for A/Darwin/6/2021 (H3N2)-like virus strain. Week 8
Secondary Seroprotection for B/Austria/1359417/2021 (B/Victoria lineage)-like virus strain (strain 3) The proportion of participants achieving seroprotection (HAI titre of =1:40) for B/Austria/1359417/2021 (B/Victoria lineage)-like virus strain. Week 8
Secondary Seroprotection for B/Phuket/3073/2013 (B/Yamagata lineage)-like virus strain (strain 4) The proportion of participants achieving seroprotection (HAI titre of =1:40) for B/Phuket/3073/2013 (B/Yamagata lineage)-like virus strain. Week 8
Secondary Proportion of participants who do not achieve seroprotection for any influenza virus strains Seroprotection is defined as HAI titre of =1:40 Week 8
Secondary Seroprotection for 1 influenza virus strain The proportion of participants achieving seroprotection (HAI titre of =1:40) for 1 influenza virus strain. Week 8
Secondary Seroprotection for 2 influenza virus strains The proportion of participants achieving seroprotection (HAI titre of =1:40) for 2 influenza virus strains. Week 8
Secondary Seroprotection for 3 influenza virus strains The proportion of participants achieving seroprotection (HAI titre of =1:40) for 3 influenza virus strains. Week 8
Secondary Seroprotection for 4 influenza virus strains The proportion of participants achieving seroprotection (HAI titre of =1:40) for all 4 influenza virus strains. Week 8
Secondary Markers of immunological function Isolation of peripheral blood mononuclear cells (PBMCs) to assess markers of immunological function. Week 0, 4 and 8
Secondary Incidence of upper respiratory symptoms Measured using the Wisconsin Upper Respiratory Symptom Survey (WURSS-24). Week 4, 8, 12 and 16
Secondary Faecal gut microbiota (composition, alpha- and beta-diversity) Measured by 16S community profiling (Illumina Miseq) of bacterial genomic DNA isolated from stool samples. Week 0, 4 and 8
Secondary Faecal short-chain fatty acids (SCFA) Measured by gas liquid chromatography of stool samples. Week 0, 4 and 8
Secondary Faecal water Determined from stool samples by oven-drying. Week 0, 4 and 8
Secondary Gut symptoms Measured using the Gastrointestinal Symptom Rating Scale (GSRS) (7-day diary; questionnaire). Week 0, 4 and 8
Secondary Stool frequency Measured using self-reported number bowel movements daily recorded in a 7-day diary. Week 0, 4 and 8
Secondary Stool consistency Measured using the Bristol stool form scale (7-day dairy; questionnaire). Week 0, 4 and 8
Secondary Serum Vitamin E levels Measured in blood sample - analysis of serum vitamin E levels by Liquid chromatography-mass spectrometry. Week 0, 4 and 8
Secondary Serum Zinc levels Measured in blood sample - analysis of serum zinc levels by automated assay. Week 0, 4 and 8
Secondary Mental health status Measured using The Patient Health Questionnaire Anxiety and Depression Scale (PHQ-ADS). Scores range from 0-48 with higher scores indicating more severe depression/anxiety. Week 0, 4 and 8
Secondary Dietary intake 7-day food and drink diary. Week 0, 4 and 8
Secondary Physical activity Measured using the International Physical Activity Questionnaire (IPAQ). Week 0, 4 and 8
Secondary Acceptability of snack products Measured using an Acceptability of dietary intervention questionnaire developed by King's College London for use in dietary intervention studies. The questionnaire assesses acceptability using a number of domains including flavour, texture, portion size. Week 8
Secondary Compliance Return of unused snacks at the final visit (consumption of >75% of total snacks will be considered compliant). Week 8
Secondary Adverse events Interview-administered questionnaire. Week 0 - 8
See also
  Status Clinical Trial Phase
Completed NCT02872311 - Open-Label Influenza Vaccine Evaluation N/A
Completed NCT01861613 - Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students Phase 4
Completed NCT03982069 - Immunologic Response to FluMist vs. Flucelvax Phase 4
Recruiting NCT06041867 - Agaricus Bisporus and Influenza Vaccination Response N/A
Completed NCT03614975 - Immunologic Response to Influenza Vaccination in Children and Adolescents Phase 4
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03875703 - Post-Vaccination Biological Collection
Completed NCT00902278 - Immune Responses Induced by Different Licensed Influenza Vaccines N/A
Completed NCT00346619 - Determining the Amount of Time Needed for Nelfinavir to Boost the Immune System in Adults Phase 1
Recruiting NCT04274348 - Staphylococcal Toxins in Atopic Dermatitis and Eczema Herpeticum N/A
Active, not recruiting NCT05534893 - Effect of Blueberries on Immunity and Response to Flu Vaccination N/A
Completed NCT05970887 - Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines Phase 4
Completed NCT05706350 - Plant Stanol Esters and Influenza Vaccination N/A
Completed NCT03167593 - Effects of Lactobacillus Coryniformis CECT5711 on Immune Response to Influenza Vaccination in Adults Over 65. Phase 2
Completed NCT04386408 - Evaluation of the Effect of a Combination of Plant Extracts (BSL_EP027) on the Incidence of Respiratory Infections Phase 1
Completed NCT02933931 - Immune Durability After VSV-EBOV Vaccination
Recruiting NCT01289535 - Immune Response Analysis to Influenza Vaccine in Elderly Aged Over 65 Years Phase 4
Active, not recruiting NCT02441426 - Interactions of Enteric Infections and Malnutrition and the Consequences for Child Health and Development N/A
Recruiting NCT03399357 - Evaluation of Metabolic Predictors of Influenza Vaccine Immune Response in the Singapore Elderly Population - the DYNAMIC Trial N/A
Recruiting NCT06404749 - Fungal Fiber for Gut Health N/A